Evaluation of the novel mitotic modulator on 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay

Oncogene

Volumn 28, Issue 4, 2009, Pages 610-618

  Jimeno, A ^a   Chan, A ^a   Cusatis, G ^a   Zhang, X ^a   Wheelhouse, J ^a   Solomon, A ^a   Chan, F ^a   Zhao, M ^a   Cosenza, S C ^b   Reddy, M V Ramana ^b   Rudek, M A ^a   Kulesza, P ^c   Donehower, R C ^a   Reddy, E P ^b   Hidalgo, M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

Biomarker; Cyclin B1; ex vivo; Mitotic modulator; Pancreatic cancer; Xenograft model

Indexed keywords

ANTIMITOTIC AGENT; CYCLIN B1; GEMCITABINE; MESSENGER RNA; ON 01910NA; PROTEIN TYROSINE PHOSPHATASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BIOPSY, FINE-NEEDLE; CDC25 PHOSPHATASES; CELL LINE, TUMOR; CYCLIN B; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; GLYCINE; HUMANS; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; SULFONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 59149102658     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.424     Document Type: Article

References (24)

1. Budirahardja Y, Gonczy P. (2008). PLK-1 asymmetry contributes to asynchronous cell division of C. elegans embryos. Development 135: 1303-1313.
2. Dvory-Sobol H, Cohen-Noyman E, Kazanov D, Figer A, Birkenfeld S, Madar-Shapiro L et al. (2006). Celecoxib leads to G2/M arrest by induction of p21 and downregulation of cyclin B1 expression in a p53-independent manner. Eur J Cancer 42: 422-426.
3. Gonczy P. (2008). Mechanisms of asymmetric cell division: flies and worms pave the way. Nat Rev Mol Cell Biol 9: 355-366.
4. Gumireddy K, Reddy MV, Cosenza SC, Boominathan R, Baker SJ, Papathi N et al. (2005). ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 7: 275-286.
5. Hassan KA, Ang KK, El-Naggar AK, Story MD, Lee JI, Liu D et al. (2002). Cyclin B1 overexpression and resistance to radiotherapy in head and neck squamous cell carcinoma. Cancer Res 62: 6414-6417.
6. Hidalgo M, Amador ML, Jimeno A, Mezzadra H, Patel P, Chan A et al. (2006). Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration. Mol Cancer Ther 5: 1895-1903.
7. Jackman M, Lindon C, Nigg EA, Pines J. (2003). Active cyclin B1-Cdk1 first appears on centrosomes in prophase. Nat Cell Biol 5: 143-148.
8. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. (2007). Cancer statistics, 2007. CA Cancer J Clin 57: 43-66.
9. Jimeno A, Kulesza P, Kincaid E, Bouaroud N, Chan A, Forastiere A et al. (2006). C-fos assessment as a marker of anti-epidermal growth factor receptor effect. Cancer Res 66: 2385-2390.
10. Jimeno A, Li J, Messersmith WA, Laheru D, Rudek MA, Maniar M et al. (2008). Phase I Study of ON 01910.Na, a novel modulator of the polo-like kinase 1 pathway, in adult patients with solid tumours. J Clin Oncol (e-pub ahead of print, 27 October 2008).
11. Jimeno A, Rubio-Viqueira B, Amador ML, Oppenheimer D, Bouraoud N, Kulesza P et al. (2005). Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. Cancer Res 65: 3003-3010.
12. Jimeno A, Tan A, Garrido-Laguna I, Solomo A, Hruban R, Schulick R et al. A prospective clinical validation of a direct xenograft pancreatic cancer approach. 2008 ASCO Annual Meeting, oral presentation. (abstract 4500).
13. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P et al. (2008). Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801-1806.
14. Korenaga D, Takesue F, Yasuda M, Honda M, Nozoe T, Inutsuka S. (2002). The relationship between cyclin B1 overexpression and lymph node metastasis in human colorectal cancer. Surgery 131: S114-S120.
15. Li J, Zhao M, Jimeno A, He P, Ramana Reddy MV, Hidalgo M et al. (2007). Validation and implementation of a liquid chromatography/ tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 856: 198-204.
16. Nigg EA. (1998). Polo-like kinases: positive regulators of cell division from start to finish. Curr Opin Cell Biol 10: 776-783.
17. Park M, Chae HD, Yun J, Jung M, Kim YS, Kim SH et al. (2000). Constitutive activation of cyclin B1-associated cdc2 kinase overrides p53-mediated G2-M arrest. Cancer Res 60: 542-545.
18. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C et al. (2006). An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 12: 4652-4661.
19. Samson DJ, Seidenfeld J, Ziegler K, Aronson N. (2004). Chemotherapy sensitivity and resistance assays: a systematic review. J Clin Oncol 22: 3618-3630.
20. Schmidt M, Hofmann HP, Sanders K, Sczakiel G, Beckers TL, Gekeler V. (2006). Molecular alterations after Polo-like kinase 1 mRNA suppression versus pharmacologic inhibition in cancer cells. Mol Cancer Ther 5: 809-817.
21. Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD, Somerfield MR. (2004). American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 22: 3631-3638.
22. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792.
23. Smits VA, Klompmaker R, Arnaud L, Rijksen G, Nigg EA, Medema RH. (2000). Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat Cell Biol 2: 672-676.
24. Yuan J, Kramer A, Matthess Y, Yan R, Spankuch B, Gatje R et al. (2006). Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo. Oncogene 25: 1753-1762.